Mode
Text Size
Log in / Sign up

Major Depressive Disorder

Subtypes of Major Depressive Disorder

Antidepressant Non-Response 1 Treatment-resistant major depression 1

57 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Major Depressive Disorder

469 trials tracked for Major Depressive Disorder: 230 in phase 3 or 4 and 65 with published results. The most-cited published study has 424 citations.

469Trials tracked
230Phase 3 & 4
0Recruiting
65With published results
Phase distribution
Phase 4 83 Phase 3 147 Phase 2 97 Phase 1 23 Other / NA 119
  1. Phase 4 Ketamine in the Treatment of Suicidal Depression Completed · 424 cited
  2. Phase 3 Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach Completed · 264 cited
  3. Phase 3 ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) Completed · 252 cited
  4. Phase 3 A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder Completed · 186 cited
  5. Phase 3 VA Augmentation and Switching Treatments for Improving Depression Outcomes Completed · 150 cited
  6. Phase 3 A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy Completed · 141 cited
Show 44 more trials
  1. Phase 3 THINC-it Vortioxetine - Sensitivity to Change Completed · 141 cited
  2. Phase 3 A Trial of AXS-05 in Patients With Major Depressive Disorder Completed · 126 cited
  3. Phase 4 Imaging Dopamine Release in Depression Completed · 97 cited
  4. Phase 3 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide Completed · 97 cited
  5. Phase 3 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide Completed · 97 cited
  6. Phase 4 Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery Completed · 91 cited
  7. Phase 3 Focal Electroconvulsive Therapy for Depression Completed · 90 cited
  8. Phase 3 A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD) Completed · 81 cited
  9. Phase 4 Does Dual Therapy Hasten Antidepressant Response? Completed · 78 cited
  10. Phase 4 Optimizing Outcomes of Treatment-Resistant Depression in Older Adults Completed · 75 cited
  11. Phase 3 A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder Completed · 64 cited
  12. Phase 3 Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone Completed · 57 cited
  13. Phase 4 ECT Pulse Amplitude and Medial Temporal Lobe Engagement Completed · 46 cited
  14. Phase 4 A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise Completed · 44 cited
  15. Phase 4 Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults Completed · 44 cited
  16. Phase 4 Trial of Levomilnacipran in Geriatric Depression Completed · 38 cited
  17. Phase 3 Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) Completed · 37 cited
  18. Phase 4 Pioglitazone in Patients With Mood Disorders Completed · 35 cited
  19. Phase 4 Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults Completed · 34 cited
  20. Phase 3 A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD Completed · 34 cited
  21. Phase 3 Study of Ibuprofen Effects on Brain Function Completed · 34 cited
  22. Phase 3 Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder Completed · 33 cited
  23. Phase 4 Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study) Completed · 24 cited
  24. Phase 4 A Study of L-DOPA for Depression and Slowing in Older Adults Completed · 24 cited
  25. Phase 3 A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder Completed · 24 cited
  26. Phase 4 Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms Completed · 22 cited
  27. Phase 3 Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms Completed · 22 cited
  28. Phase 3 The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone Completed · 21 cited
  29. Phase 4 Ketamine Infusion for Adolescent Depression and Anxiety Completed · 20 cited
  30. Phase 3 A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial Completed · 20 cited
  31. Phase 4 Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) Completed · 18 cited
  32. Phase 4 A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder Completed · 18 cited
  33. Phase 3 A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder Completed · 18 cited
  34. Phase 4 Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder Completed · 15 cited
  35. Phase 3 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder Completed · 15 cited
  36. Phase 3 A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) Completed · 15 cited
  37. Phase 4 Connectivity Affecting the Antidepressant REsponse Study Completed · 13 cited
  38. Phase 3 A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD) Completed · 13 cited
  39. Phase 3 Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial) Completed · 13 cited
  40. Phase 4 Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers Completed · 12 cited
  41. Phase 3 A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder Completed · 12 cited
  42. Phase 3 A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Completed · 12 cited
  43. Phase 3 A Study in Prevention of Re-emergence of Depression Symptoms Completed · 10 cited
  44. Phase 4 Study of Naltrexone-Induced Blockade of Antidepressant Effects Completed · 7 cited

Showing the 50 most-cited and recently-updated of 469 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Major Depressive Disorder

Can text-message cognitive-behavioral therapy help reduce symptoms of major depressive disorder in young adults?

Yes, text-message CBT (CBT-txt) significantly reduces depressive symptoms in young adults with major depressive disorder, based on multiple randomized trials.

Full answer →
Does adding JNJ-42165279 help people whose major depressive disorder did not improve on current antidepressants?

No, JNJ-42165279 did not improve depression in a clinical trial of people whose SSRI/SNRI was not working well enough.

Full answer →
Is Auvelity the new FDA-approved medication for treating major depressive disorder in adults?

Yes, Auvelity (dextromethorphan/bupropion) is FDA-approved for treating major depressive disorder in adults.

Full answer →

All Major Depressive Disorder Articles